Cargando…

Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers

BACKGROUND: Systemic bevacizumab is a novel targeted anti-angiogenic therapy for high-output cardiac failure (HOCF) in hereditary hemorrhagic telangiectasia (HHT) but published data is limited. This survey-based study measured physician-reported safety, effectiveness and current treatment practices...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Samkari, Hanny, Albitar, Hasan A., Olitsky, Scott E., Clancy, Marianne S., Iyer, Vivek N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857247/
https://www.ncbi.nlm.nih.gov/pubmed/31727111
http://dx.doi.org/10.1186/s13023-019-1239-6